Edition:
United Kingdom

Eagle Pharmaceuticals Q3 earnings per share $0.98


Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Eagle Pharmaceuticals Inc :Eagle Pharmaceuticals Inc reports third quarter 2017 results.Q3 adjusted non-GAAP earnings per share $1.22.Q3 earnings per share $0.98.Q3 revenue $63 million versus I/B/E/S view $51.9 million.Q3 earnings per share view $0.80 -- Thomson Reuters I/B/E/S.Expect full year 2017 research and development expense will be consistent with upper end of $31-$35 million range​.Plan to begin dosing patients in Fulvestrant study in a few weeks and expect to file an NDA in Q4 of 2018​.Expect full year 2017 SG&A expense to be in range of $67 million - $70 million, slightly higher than previous guidance​.Will continue purchasing up to an additional $100 million shares under current share repurchase plan​.On PEMFEXY, says "hope to find a way to market" as soon as possible, once co's litigation with Eli Lilly is resolved​. 

Company Quote

54.3
0.76 +1.42%
24 May 2019